Reno, Nevada – Conexeu Sciences Inc. (“Conexeu” or the “Company”), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based regenerative therapies.
“We’re honored to welcome Aaron and Sebastian to Conexeu’s Board,” said Jeff Sharpe, Chairman of the Board of Directors. “Aaron brings unmatched clinical and scientific expertise in regenerative dermatology, while Sebastian contributes a rare blend of ethical clarity and strategic vision. Their combined perspectives will help shape Conexeu’s growth as we bring our collagen technologies from the lab to real-world patient impact.”
Dr. Farberg, a nationally recognized dermatologist, surgeon, and researcher, is celebrated for his groundbreaking work in medical, aesthetic, and reconstructive dermatology. He serves as Chief Medical Officer and Founding Partner Dermatologist at Bare Derm Group, Executive Director and Principal Investigator at Reveal Research Institute, and holds multiple academic appointments across Texas. In 2023, NEWSWEEK named him the #1 Dermatologist in Texas and #5 in the United States, recognizing his clinical excellence and research leadership.
Dr. Purcell, a philosopher and investor, brings a complementary dimension of strategic insight and ethical perspective to the Board. He is the Chief Executive Officer and Chief Investment Officer of 1.2 Capital, an alternative investment management firm focused on digital assets, venture, and macro strategies. With a Ph.D. in Philosophy from Boston College, Dr. Purcell’s academic research bridges ethics, mathematics, and logic. His work has earned awards from the American Philosophical Association, the National Endowment for the Humanities, and the National Endowment for the Arts, and he has lectured at Princeton, Columbia, and McGill Universities. His commentary and thought leadership have been featured in The Guardian, BBC World, and Time Magazine.
“The addition of Aaron and Sebastian to the Board strengthens not just our governance, but our purpose,” said Miles Harrison, President, Chief Executive Officer, and Board Member of Conexeu Sciences. “Aaron and Sebastian embody the scientific rigor, ethical conviction, and forward thinking that define Conexeu. We are leading the next evolution of regenerative tissue by delivering scalable, clinically proven and economically viable ‘collagen-based solutions’ that minimize risk and maximize patient outcomes.”
Both new Board members expressed enthusiasm about joining Conexeu during a pivotal phase of innovation and expansion. “Conexeu is redefining what’s possible in regenerative medicine,” said Dr. Farberg. “Conexeu’s technologies have the power to improve how we heal, from chronic wounds to aesthetic procedures, and I’m excited to help guide its continued clinical progress.”
“Regenerative medicine represents not just a scientific frontier, but an ethical one,” added Dr. Purcell. “Conexeu’s commitment to human-centered innovation reflects the kind of responsible, purpose-driven progress that will define the next generation of biotechnology.”
Read Original Release: https://www.newsfilecorp.com/release/273243/Conexeu-Sciences-Inc.-Expands-Board-of-Directors-with-the-Appointments-of-Dr.-Aaron-Farberg-and-Dr.-Sebastian-Purcell
